Posted on: May 1, 2013 by Staff
Celator Pharmaceuticals Inc., clinical-stage biopharmaceuticals company focused on cancer treatment, has raised US$32.5 million in the final closing of a private placement of common stock and warrants to purchase common stock. The deal was led by U.S. venture capital firm Valence Life Sciences. Celator, which has offices in Vancouver and Princeton, New Jersey, has been venture-backed since 2002. Its other investors include BDC Venture Capital, Domain Associates, GrowthWorks, Hearthstone Investment, Quaker BioVentures, TL Ventures and Ventures West Capital.
Tags: BDC Venture Capital, Celator Pharmaceuticals Inc., Domain Associates, GrowthWorks, Hearthstone Investment, Quaker BioVentures, TL Ventures, Valence Life Sciences, Ventures West Capital
Posted on: November 12, 2012 by asormani
Fabrice Egros has been appointed COO, pharmaceutical director and board member of NovaMedica. The business was established as part of the $760 million collaboration between the Russian high technology investment fund RUSNANO and the American health care venture fund Domain Associates.
Tags: Domain Associates, RUSNANO
Posted on: October 10, 2012 by Luisa Beltran
RightCare Solutions has secured $1.75 million in Series A funding led by Compass Partners and Domain Associates. RightCare, of Ft. Washington, Pa., specializes in hospital discharge planning and readmission management.
Tags: Compass Partners, Domain Associates, RightCare Solutions
Posted on: September 26, 2012 by asormani
Apnex Medical has secured financing totaling $10 million from New Enterprise Associates. The funds will be used to support the ongoing Apnex Clinical Study. Apnex develops medical devices aimed at helping people with sleep apnea. Other investors in the company include Domain Associates, Polaris Venture Partners and investor and Apnex chairman Michael Berman.
Tags: Domain Associates, New Enterprise Associates, Polaris Venture Partners
Posted on: September 11, 2012 by asormani
Tobira Therapeutics, a developer of innovative antiretroviral therapies for HIV, has appointed three executives in the finance, clinical and pharmaceutical sciences functions. Caroline Loewy joins the company as executive vice president and chief financial officer, Jeff Enejosa, M.D., as senior director, clinical research, and Mark Menning as director, pharmaceutical sciences. Tobira has financial backing from [...]
Tags: Canaan Partners, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures
Posted on: July 25, 2012 by asormani
CoDa Therapeutics has raised an additional $20 million from RusnanoMedInvest in a second close of its Series B financing round. This brings the total Series B Round to nearly $40 million following the first close late last year. All current investors, including Domain Associates, GBS Ventures and BioPacificVentures participated. San Diego-based CoDa is a biopharmaceutical [...]
Tags: BioPacificVentures, Domain Associates, GBS Ventures, RusnanoMedInvest
Posted on: June 7, 2012 by Jonathan Marino
Astute Medical, the San Diego-based biomarker-based medical diagnostics firm, took in more than $40 million in a big Series C round, the company revealed. The financing was led by MPM Capital, and included new investor Kaiser Permanente Ventures. Prior backers De Novo Ventures, Delphi Ventures, Domain Associates and Johnson & Johnson Development Corporation also joined [...]
Tags: De Novo Ventures, Delphi Ventures, Domain Associates, MPM Capital
Posted on: May 22, 2012 by asormani
Benvenue Medical, a developer of minimally invasive solutions for spine repair, has appointed two new members to its board of directors. Thomas M. Prescott, president and CEO of Align Technology and Thomas C. Wilder, president and CEO of Sequent Medical are both experienced in bringing medical technologies to the global marketplace. Investors in Benvenue Medical [...]
Tags: DeNovo Ventures, Domain Associates, Technology Partners, Versant Ventures
Posted on: March 6, 2012 by reuters-news
Russian state technology firm Rusnano is teaming up with a US venture fund, writes Reuters. Rusnano and life sciences technologies investor Domain Associates are planning to co-invest in about 20 US-based healthcare technology companies. Rusnano will invest up to $330 million and Domain’s venture capital funds and other investors will invest a like amount, according [...]
Tags: Domain Associates, RUSNANO
Posted on: January 18, 2012 by cnolan
Carticept Medical Inc., a developer of treatments for cartilage injuries and osteoarthritis, has raised $10 million in financing led by existing investors Domain Associates, New Enterprise Associates and SonoSite Inc. The money is aimed at commercial launch of the company’s computer-controlled drug delivery system. In total, Carticept has raised $53 million from investors.
Tags: Domain Associates, New Enterprise Associates